Aurobindo receives USFDA nod for Efavirenz

New Delhi, Dec 22 (UNI) Aurobindo Pharma Ltd today said it has received tentative approval from the US Food and Drug Adminsitration (USFDA) for Efavirenz capsules, 50 mg, 100 mg and 200 mg.

This is the company's 33rd generic approval given by US FDA and 18th in ARV line. In addition, this is first generic alternative to 'Sustiva Capsules' of Bristol Myers Squibb Co.

Efavirenz is a key ARV in the Anti aids therapy. It represents a significant opportunity in Africas for the company under PEPFAR programme.

The drug is in the class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), which helps keep the AIDS virus from reproducing in cells. It is used in the combination with other NRTI drugs.

UNI DKS PV DS1525